- Home
- FHTX vs BWFG Comparison
FHTX vs BWFG Comparison
Compare FHTX & BWFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHTX
- BWFG
- Stock Information
- Founded
- FHTX 2015
- BWFG 2002
- Country
- FHTX United States
- BWFG United States
- Employees
- FHTX N/A
- BWFG N/A
- Industry
- FHTX Medicinal Chemicals and Botanical Products
- BWFG Major Banks
- Sector
- FHTX Health Care
- BWFG Finance
- Exchange
- FHTX Nasdaq
- BWFG Nasdaq
- Market Cap
- FHTX 237.4M
- BWFG 256.5M
- IPO Year
- FHTX 2020
- BWFG N/A
- Fundamental
- Price
- FHTX $4.40
- BWFG $29.89
- Analyst Decision
- FHTX Strong Buy
- BWFG Buy
- Analyst Count
- FHTX 5
- BWFG 1
- Target Price
- FHTX $13.80
- BWFG $40.00
- AVG Volume (30 Days)
- FHTX 170.9K
- BWFG 15.3K
- Earning Date
- FHTX 03-06-2025
- BWFG 01-22-2025
- Dividend Yield
- FHTX N/A
- BWFG 2.64%
- EPS Growth
- FHTX N/A
- BWFG N/A
- EPS
- FHTX N/A
- BWFG 1.94
- Revenue
- FHTX $25,515,000.00
- BWFG $72,009,000.00
- Revenue This Year
- FHTX N/A
- BWFG N/A
- Revenue Next Year
- FHTX $7.37
- BWFG $9.07
- P/E Ratio
- FHTX N/A
- BWFG $15.59
- Revenue Growth
- FHTX N/A
- BWFG N/A
- 52 Week Low
- FHTX $2.70
- BWFG $22.47
- 52 Week High
- FHTX $10.25
- BWFG $35.25
- Technical
- Relative Strength Index (RSI)
- FHTX 33.35
- BWFG 47.25
- Support Level
- FHTX $4.13
- BWFG $29.35
- Resistance Level
- FHTX $4.52
- BWFG $30.89
- Average True Range (ATR)
- FHTX 0.34
- BWFG 0.86
- MACD
- FHTX 0.08
- BWFG 0.10
- Stochastic Oscillator
- FHTX 20.88
- BWFG 57.69
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
About BWFG Bankwell Financial Group Inc.
Bankwell Financial Group Inc is a bank holding company, engaged in providing financial products and services. It offers products related to commercial lending, retail lending, depository services, and others. The bank's commercial lending products includes owner-occupied commercial real estate loans, commercial real estate investment loans, commercial loans to small and mid-sized businesses, and real estate construction and development loans. The retail lending products include residential mortgage loans, home equity lines of credit, and consumer installment loans. Its depository products include checking, savings, money market, certificates of deposit, noninterest-bearing demand, and time deposits.